MS race: how does speed affect our patients?
Author(s): ,
R. Alonso
Affiliations:
Neurology, Multiple Sclerosis Clinic. University Centre of Neurology - J. M. Ramos Mejía Hospital, Buenos Aires City, Argentina
,
M.B. Eizaguirre
Affiliations:
Neurology, Multiple Sclerosis Clinic. University Centre of Neurology - J. M. Ramos Mejía Hospital, Buenos Aires City, Argentina
,
B. Silva
Affiliations:
Neurology, Multiple Sclerosis Clinic. University Centre of Neurology - J. M. Ramos Mejía Hospital, Buenos Aires City, Argentina
,
M.C. Pita
Affiliations:
Neurology, Multiple Sclerosis Clinic. University Centre of Neurology - J. M. Ramos Mejía Hospital, Buenos Aires City, Argentina
,
S. Vanotti
Affiliations:
Neurology, Multiple Sclerosis Clinic. University Centre of Neurology - J. M. Ramos Mejía Hospital, Buenos Aires City, Argentina
O. Garcea
Affiliations:
Neurology, Multiple Sclerosis Clinic. University Centre of Neurology - J. M. Ramos Mejía Hospital, Buenos Aires City, Argentina
ECTRIMS Online Library. Alonso R. Oct 12, 2018; 228868; P1026
Ricardo Alonso
Ricardo Alonso
Contributions
Abstract

Abstract: P1026

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - Clinical assessment tools

Background: Beyond the Expanded Disability Status Scale (EDSS), there are other measurements that assess disability in patient with MS (PwMS). The MS Functional Composite (MSFC) is a standardized and quantitative assessment mainly used in clinical trials. MSFC measure lower extremity (LE) function, upper extremity (UE) function, and cognitive function, using speed tests. Speed ​​measures have been shown to be sensitive to assess disability in PwMS. On the other hand, quality of life (QoL) measurements are being considered increasingly important with regard to evaluating disease progression and treatment.
Objective: 1) To analyze the associations between speed measurements (UE, LE, Cognition) and disability, with QoL of PwMS. 2) To determine the predictive value of mentioned variables on the QoL.
Method: 52 PwMS were evaluated. 34 were women (65,4%). The age mean was 40,62 ± 14,70 years old. Mean EDSS was 2,48 ± 1,65, and the disease evolution mean was 11,87 ± 3,45 years. 92% of the patients had Relapsing-Remitting Multiple Sclerosis. LE and UE function were assessed with Timed 25 Foot Walk (T25FW) and Nine Hole Peg Test (NHPT) respectively. Information processing speed with Paced Auditory Serial Addition Test (PASAT) and Symbol Digit Modalities Test (SDMT). Health-related Qol with MS Quality of life (MusiQuol). A descriptive analysis was carried out on all the variables included. The association between all variables were analyzed with Spearman correlation and lineal regression was undertaken to determine which variable are most predictive of QoL
Result: Significant associations were found between SDMT, PASAT, NHPT, EDSS and the following QoL subscales: activities of daily living (ADL) (r:-.557 to .391; p: < .05), psychological well-being (PWB) (r:-.358 to .386; p: < .05) and Symptoms (SPT) (r: -.360 to .454; p: < .05). T25FW correlated with ADL(r: -.377; p: .008). In the regression analysis, the SDMT and PASAT were established as predictors of SPT (R²:.274; p: < .001; β: .523) and PWB (R²: .116; p: .019; β: .340) respectively. NHPT were established as predictors of ADL (R²:.325; p: < .001; β.570).
Conclusions: In the present study we found a robust association between measures of cognitive and UE speed with different aspects of QoL. Other measures beyond the EDSS should be taken into account for the follow-up of the PwMS.
Disclosure: Alonso Ricardo has received reimbursement for developing educational presentations, educational grants and travel stipends from Biogen, Genzyme, Merck, Novartis and Roche.
Eizaguirre Maria Barbara nothing to disclose
Silva Berenice nothing to disclose
Pita Maria Cecilia nothing to disclose
Vanotti Sandra has received reimbursement for developing educational presentations from Biogen Argentina and Novartis Argentina
Garcea Orlando has received reimbursement for developing educational presentations, educational and research grants, consultations fees and travel stipends from Biogen, Genzyme, Merck.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies